Skip to main content

Table 3 P-values of univariate and multivariate analyses for OS, DP, and LC. Multivariate analysis was performed with the significant items of univariate analysis

From: Stereotactic body radiotherapy (SBRT) in patients with lung metastases - prognostic factors and long-term survival using patient self-reported outcome (PRO)

  OS (n = 219) DP (n = 219) LC (n = 316)
UVA MVA UVA MVA UVA MVA
Age at RT° 0.667 0.630 0.003* 0.320
Gender 0.401 0.092 0.220
KPS (< 90 vs. ≥90%) < 0.001* < 0.001* < 0.001* < 0.001* 0.844
Primary tumor type (NSCLC vs CRC vs. Melanoma vs. Breast) 0.985 0.954 0.437
GTV° < 0.002* 0.439 0.035* 0.919 0.762
GTV (< 8 vs ≥8 ml) < 0.001* 0.005* 0.844
PTV° 0.003* 0.904 0.046* 0.599 0.211
PTV (< 35 vs ≥35 ml) < 0.001* 0.017* 0.842
Planning PET-CT 0.264 0.765 0.133
Number of pulmonary METs (≤3 vs. > 3) < 0.001* 0.014* 0.078 < 0.001* < 0.001*
Absence extra thoracic MET < 0.001* 0.020* < 0.001* < 0.001* 0.859
Controlled primary tumor < 0.001* < 0.001* 0.001* 0.003* 0.632
CHT between MET diagnosis and SBRT 0.047* 0.176 0.468 0.097
BED10iso° 0.001* 0.289 0.413 0.429
BED10PTVmean° 0.007* 0.468 0.439 0.955
Time from primary diagnosis to MET diagnosis° 0.090 0.985 0.882
Time from primary diagnosis to MET diagnosis (< 12 vs. ≥12 months) 0.884 0.291 0.336
  1. UVA Univariate analysis, MVA Multivariate analysis, OS Overall survival, DP Distant progression, LC Local control, KPS Karnofsky Performance Score, RT Radiotherapy, CHT Chemotherapy, MET Metastasis, PTV Planning target volume, GTV Gross tumor volume, NSCLC non-small cell lung cancer, CRC colorectal carcinoma, * significant p-value, ° continuous variable